BCTXW (BriaCell Therapeutics) ROCE %: -106.99% (As of Apr. 2026)


BCTXW BriaCell Therapeutics Corp BCTXW
23 GF Score
Price $0.00
! 2 Warning Signs
View Full Analysis

What is BriaCell Therapeutics ROCE %?

BriaCell Therapeutics BCTXW 23 ROCE % is -106.99% as of Apr. 2026. GuruFocus rates BCTXW with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. BriaCell Therapeutics's annualized ROCE % for the quarter that ended in Apr. 2026 was -106.99%.

BriaCell Therapeutics  (NAS:BCTXW) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

BriaCell Therapeutics ROCE % Related Terms

BriaCell Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for BriaCell Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BriaCell Therapeutics ROCE % Chart

BriaCell Therapeutics Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -50.84 -54.15 -69.47 -41.49 -329.78

BriaCell Therapeutics Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -294.60 -215.25 -242.75 -150.00 -106.99
BCTXW
23GF Score
BriaCell Therapeutics Corp BCTXW
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BriaCell Therapeutics ROCE % Calculation

BriaCell Therapeutics's annualized ROCE % for the fiscal year that ended in Jul. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jul. 2025 )  (A: Jul. 2024 )(A: Jul. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jul. 2025 )  (A: Jul. 2024 )(A: Jul. 2025 )
=-26.519/( ( (5.872 - 7.461) + (21.65 - 3.978) )/ 2 )
=-26.519/( (-1.589+17.672)/ 2 )
=-26.519/8.0415
=-329.78 %

BriaCell Therapeutics's ROCE % of for the quarter that ended in Apr. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Apr. 2026 )  (Q: Jan. 2026 )(Q: Apr. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Apr. 2026 )  (Q: Jan. 2026 )(Q: Apr. 2026 )
=-28.828/( ( (33.594 - 3.186) + (27.071 - 3.59) )/ 2 )
=-28.828/( ( 30.408 + 23.481 )/ 2 )
=-28.828/26.9445
=-106.99 %

(1) Note: The EBIT data used here is four times the quarterly (Apr. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -106.99% mean?
BriaCell Therapeutics (BCTXW) has a ROCE % of -106.99% as of Apr. 2026.
Is BriaCell Therapeutics' ROCE % too high?
BriaCell Therapeutics' current ROCE % is -106.99%. Overall, BriaCell Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does BriaCell Therapeutics' ROCE % compare to VRTX and REGN?
BriaCell Therapeutics' ROCE % of -106.99% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. BriaCell Therapeutics's current ROCE % is -106.99%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BriaCell Therapeutics stock overvalued right now?
BriaCell Therapeutics (BCTXW) has a current ROCE % of -106.99%. The current ROCE % is -106.99%. BriaCell Therapeutics' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For BriaCell Therapeutics (BCTXW), the current ROCE % is -106.99% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BriaCell Therapeutics Business Description

Address 235-15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
23GF Score

Get the complete analysis for BCTXW

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price